420 with CNW — Recent Studies Show Advanced Cancer Sufferers Could Benefit from Using Marijuana

Over the past couple of years, a surge in cannabis research has revealed that the controversial plant has a variety of medical applications. Despite being classified as a Schedule I drug with no medical application, studies have found that cannabis can be effective at alleviating conditions such as chronic pain, depression and insomnia. Furthermore, the U.S. Food and Drug Administration has also approved a CBD-based drug called Epidiolex to treat seizures in pediatric epilepsy.

In recent months, research into the impact of cannabis on cancer treatment has found that the plant can have a positive impact on cancer patients. Cancer is one of the deadliest killers in the country, taking more than 500,000 lives per year and costing billions of dollars for treatment. Although there are treatments that can stop cancers from growing and significantly increase patients’ quality of life, no cure for cancer currently exists.

Researchers have been working on developing new treatments for the deadly disease, with cannabis being one of the objects of interest. Cancer is often associated with costly and addictive pain medications, reduced life quality, and mental and emotional anguish. And while most cancer treatments are geared at alleviating physical discomfort, there are barely any treatments designed to treat the mental and psychological anguish that comes from having a severe or terminal illness.

Upstate University Hospital researchers sought to understand how cannabis could benefit cancer treatment by studying how advanced cancer patients reacted to medical cannabis treatment. Study authors write that the goal of the research was to analyze the characteristics of advanced cancer patients who had received medical cannabis under a palliative care program and to point out any barriers that prevent patients with cancer from accessing medical marijuana.

Study participants had to be enrolled in New York’s medical cannabis registry. Researchers from the Upstate University Hospital in Syracuse reviewed patient data that was collected from June 2017 to June 2020, analyzing data from patients who had been diagnosed with cancer by a practitioner who is certified by the New York Medical Marijuana program and who had received treatment at Upstate Medical University.

The researchers found that medical cannabis use had a positive impact on advanced cancer patients, with 48.14% of the patients who received a dose of medical marijuana reporting reduced pain, 44.95% saying that they used fewer opioids as a result, and 85.11% noting that cannabis use alleviated at least one symptom. Only 3.72% of the patients who used cannabis reported feeling any adverse effects.

Researchers concluded that medical cannabis seems to play a role in alleviating symptoms of advanced cancer with minimal side effects and called for more research to determine optimal delivery methods and doses for patients. In this regard, industry players such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are leading the way by coming up with different innovations that optimize consumers’ experience while using marijuana products.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Gallup Poll Finds Americans Think Cannabis Better than Alcohol for Society

Consecutive surveys over the past couple of years have revealed that attitudes toward cannabis have been steadily shifting toward the positive. After decades of criminalization, over policing, harsh sentencing and anti-cannabis propaganda, a large swathe of the population believed cannabis was just as dangerous as hard-core drugs such as cocaine and heroin.

But as cannabis reform has swept over the country for the past two decades, consumers have been increasingly inclined to shed their preconceived notions about cannabis. This is largely due to the fact that studies have shown that the controversial plant has a wide range of medical applications.

A new poll by Gallup, which has conducted several cannabis-related surveys in the past, shows that Americans believe that marijuana is much better for people and society compared to alcohol. The survey found that the number of Americans who believe cannabis has a positive impact on users and the community at large is more than double the number of Americans who have the same opinion about alcohol. Furthermore, the poll revealed that cannabis users were much more likely to extoll its pros compared to a small portion of alcohol drinkers who believed alcohol had a positive impact.

A reported 53% of the Americans surveyed said that cannabis had a “positive impact” on users compared to 45% who said it had a negative impact. Regarding the plant’s impact on society, 49% said that cannabis had a good impact while 50% said its impact on society has been negative. On the other hand, 27% of the people who were polled said alcohol was good for the drinker, and 23% stated that alcohol had a positive societal impact.

A majority — 75% — believed that alcohol has a net negative impact on society, and 71% said that it isn’t good for individual drinkers either. This is despite the fact that the manufacture and sale of alcohol is legal at the federal level while cannabis is still outlawed.

Some 70% of people who had used cannabis in the past were far more likely to say that it had a positive impact, and 66% believed it had a positive societal impact compared to 32% and 27% of drinkers who felt alcohol had a positive impact on consumers and society respectively.

An estimated 37% of non-cannabis users said cannabis was good for users, and 27% said it was good for society at large. In comparison, only 14% of non-alcohol-drinkers said it had a net positive impact on drinkers and society,

Overall, the Gallup poll shows that people’s perceptions of these two drugs don’t seem to be in line with federal law; the poll revealed a stark contrast between how the public sees cannabis vs. alcohol.

That shift in attitude toward marijuana is evident in the way the sales of licensed marijuana companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are generally on an upward trajectory despite the industry being flooded by plenty of players.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — New York to Start Receiving Social Equity Cannabis Business Applications

One thing most experts agree on is that the war on drugs was a failure, leading to the incarceration of tens of thousands of people on minor drug charges and decimating communities of color. As such, most state marijuana legalization bills contain social equity provisions that are meant to reinvest in these historically disadvantaged and overpoliced communities.

New York, which legalized recreational cannabis in early 2021, is set to start receiving applications for social equity retail licenses. State officials recently announced that the license application period will last from Aug. 25, 2022, to Sept. 26, 2022, with Albany TV station WRGB reporting that only qualified social-equity applicants will be able to tender their applications to the New York Office of Cannabis Management.

Titled Conditional Adult Use Retail Dispensary permits, these licenses will not be available to the general public. They are the latest in state efforts to ensure that the first recreational cannabis sales in New York benefit entrepreneurs who were directly affected by the decades-long war on drugs. According to WRGB, the social-equity license application program is part of the state’s Seeding Opportunity Initiative.

Candidates wishing to apply for a social-equity retail license must meet two conditions: they or a family member must have a cannabis-related arrest or conviction on their record and they should have experience running a business enterprise. Social-equity provisions are meant to reinvest in and rebuild communities that bore the brunt of the drug war and ensure communities of color benefit from recreational cannabis sales.

Cannabis has proven to be an extremely profitable product, employing hundreds of thousands of people and making the industry one of the fastest-growing sectors in the country. New York’s recreational cannabis sector is expected to be as profitable, generating billions of dollars once sales begin. Office of Cannabis Management executive director Chris Alexander says that the state is keen on removing barriers to entry that have prevented low-income communities of color that were most affected by the drug war from entering cannabis markets in other states.

New York’s recreational cannabis bill allows adults aged 21 and older to possess and consume certain amounts of cannabis. However, the 2021 Marijuana Regulation and Taxation Act doesn’t allow retail sales, and the Office of Cannabis Management has been forced to send cease and desist to more than 50 businesses that were selling cannabis illegally. Once social-equity businesses begin the first recreational sales in New York, state regulators will work on unveiling other licenses and dispensaries.

This emphasis on social equity brings to fruition one of the longstanding dreams that the marijuana industry, including actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS), has had in seeking to push for reforms and end the lopsided enforcement of marijuana prohibition.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Alcohol vs. Marijuana: How These Industries Are Coping with Inflation

Many often look at the alcohol industry as a way to get ideas about the trajectory that the nascent marijuana industry could take, and this comparison couldn’t be more necessary at this time when inflation is soaring, and different sectors are reeling. Let’s take a look at these two industries to see how exactly they are being impacted by inflation and how they are coping.

As you may be aware, alcohol is legal at the federal level and can be bought in a variety of places, including restaurants, bars and even convenience stores. This varied access somehow provides a cushion for customers to access the product while being pocket wise. For example, someone who could have taken several beers at a bar may decide to purchase a six-pack at a store and consume the beer at home.

The person will still drink as many beers as they usually do, but the unit cost may go down because they changed where they source the beer. This doesn’t mean it is all sunshine and smiles for the alcohol industry because prices are rising in different segments and manufacturers are reeling under the supply chain issues that have come at a time when inflation is surging.

In contrast, marijuana is still prohibited federally and can only be bought at licensed dispensaries or retail outlets in the states where the substance was legalized. You may think that this exposes marijuana consumers to the immediate effects of inflation, but the reality is that cannabis prices have been declining in several states as more players enter the industry and competition stiffens.

However, that doesn’t mean the industry isn’t feeling the pinch resulting from inflation. For now, companies are using different methods, including reducing product variety and laying off staff, to keep their operational costs from skyrocketing. Neither of these mechanisms is ultimately good for the consumer because fewer products mean that a time will come when those carrying what you want will increase the price, and you will have no alternative source for the same product. As for job cuts, you know what that means for the local economy.

As prices of inputs, such as fertilizers, keep rising, a time will come when marijuana growers have no choice but to adjust their prices in order to remain in business. When that happens, the most price-sensitive buyers may find themselves in a tight spot as prices increase across the board. This could have serious ramifications for patients who depend on medical marijuana to manage their health conditions.

At the moment, different industry players such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are implementing their own coping mechanisms while shielding the customer, and it remains to be seen how far these can go before the customer is called upon to bear their share of the burden caused by the current inflationary environment.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Report Says Senate Intelligence Committee Chair Toned Down Cannabis Amendment to Ease Bill Passage

Cannabis reform is still quite controversial. Reform activists have had a hard time getting reform past lawmakers who oppose cannabis for a variety of reasons. In many cases, they have been forced to give up certain provisions in their cannabis initiatives to make them more palatable to Republican and Democratic lawmakers who were withholding their support. A recent report from the Senate Intelligence Committee has revealed that the panel did just that last month.

In late June, the Senate committee voted in favor of a measure that would make it possible for people who had used cannabis in the past to work for intelligence agencies such as the Central Intelligence Agency (CIA) and the National Security Agency (NSA). The measure was then attached to the Intelligence Authorization Act, which was slated to go through both chambers before reaching the president’s desk. However, the report says that the committee adopted a scaled-back version of the original proposal instead.

The original version, which would have provided cannabis users with even more protections, was dialed down to make it more attractive and increase its chances of passing. In fact, the vote tally reveals that the scaled-back version of the proposal even drew the support of notorious antilegalization lawmaker Senator Tom Cotton. The proposal was first introduced by Senator Ron Wyden and attached to the Intelligence Authorization Act as an amendment.

The report notes that the proposal would have barred any federal agency from limiting their employees’ access to classified information due to past or current marijuana use. However, a scaled-back, second-degree amendment from Chairman Mark Warner and Senator Michael Bennet toned down Wyden’s original proposal and limited cannabis protections to individuals working for federal intelligence agencies.

Furthermore, the scaled-down amendment changed the language from “past or present” marijuana use to “pre-employment” marijuana consumption. According to a spokesperson from Warner’s office, Warner offered the revised proposal after the first version of the amendment failed to garner enough votes. Ultimately, the revised amendment passed in an 11 to 5 vote that saw notable members of the senate such as Senators Cotton, Diane Feinstein and Susan Collins — all of whom have a long history of opposing cannabis reform — supporting the legislation.

However, this vote may be indicative of a shift in perspective for the two latter senators, especially in regard to modest cannabis reform. Collins has previously supported proposals on access to cannabis by veterans and cannabis banking reform while Feinstein is a proponent of cannabis research.

While the cannabis industry and its actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) would have preferred to see sweeping marijuana reforms at the federal level, the incremental approach now seems the more realistic way, and advocates need to exercise patience as the process plays out over time.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — New Research Finds Legalization Hasn’t Increased Number of Teens Trying Cannabis

Concerns around how the legalization of marijuana for adult use may prompt an increase in the number of young users have been floated by both parents and health researchers since talks on legalization began a decade ago. Critics against the policy change have even gone as far as to issue warnings with no evidence to back the claims. However, new research has found that the legalization of marijuana does not cause more young individuals to try using the substance.

The study, which was conducted by researchers at Michigan State University, found that legalized marijuana retail sales did not increase the number of underage individuals who consumed cannabis. The researchers cited existing studies on the use of alcohol among the youth to highlight the importance between prevalence and incidence. Research from 2016 and 2018 shows that a big proportion of youth in the United States did not drink alcohol until they could legally. The researchers theorized that the same trend could be true with marijuana.

For their study, the researchers used public data of individuals aged between 12 and 20, then those aged 21 and above, obtained from the National Survey on Drug Use and Health. They analyzed the data using the event study model in an attempt to evaluate the causal effect legalization had on marijuana use. This is in addition to projecting levels of cannabis use if legalization hadn’t been enacted.

They discovered that legalizing adult-use marijuana did increase first-time marijuana consumption — but only among individuals who could use the drug legally once the policy change was enacted. In their report, the researchers noted that they observed no evidence of an increase in use among underage individuals.

The lead author of the study, Barrett Wallace Montgomery, stated that by contrast, the number of individuals aged 21 and above who were trying marijuana for the first time after adult-use legalization could double or triple.

NORML, a marijuana advocacy group, stated in a recent blog post that the study’s findings were consistent with previous research, which had shown that adult-use legalization wasn’t linked to increased access or use among young individuals.

The study was partly funded by the National Institutes of Health and its findings were published in the “PLOS One” journal. The study claims to be the first one designed to assess incidence of use as a result of the legalization of adult-use cannabis. Prior studies have centered on prevalence, trying to measure the effect legalization has had on how much marijuana individuals use or how often they use it.

Marijuana industry actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) will be pleased to see that independent studies are confirming what they knew all along —rather than increasing underage access, creating legal markets would limit how easy it is for youth to get their hands on marijuana.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Federal Health Agencies Consider Funding Research into Minor Cannabinoids

If you ask the average American if they know what cannabinoids are, they’ll probably mention delta-9 THC, the main psychoactive component in cannabis, or cannabidiol (CBD). These are the most abundant cannabinoids in the cannabis plant as well as the most popular. As a result, they have received a lot of public and scientific attention in the past couple of years amid sweeping cannabis reform.

What many people don’t know is that the cannabis plant produces more than 100 cannabinoids, although most of them occur in small quantities. Cannabis also produces a variety of terpenes and flavonoids that significantly impact the quality of the final product. A group of federal health agencies is now looking into funding research on the possible therapeutic benefits of minor cannabinoids and cannabis terpenes.

The announcement was made via a notice of special interest (NOSI) posted by the National Institutes of Health (NIH) and eight of its component agencies; the NOSI was titled “Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes.”

Every cannabinoid except THC is considered a minor cannabinoid. While THC has been subject to plenty of research, especially in recent years, there is little scientific research on lesser-known or minor cannabinoids, including CBN, CBG and delta-8 THC. The notice states that the agencies are interested in studies involving model organisms and human subjects that look into the impact of terpenes and minor cannabinoids.

The notice goes on to say there is specific interest in preclinical studies of minor cannabinoid-terpene combinations and combinations of minor cannabinoids and other natural products that could enhance health benefits and tamp down on side effects. The notice stated that terpenes and minor cannabinoids may be able to alleviate a wide variety of pathological diseases and conditions; it also encouraged experts from multiple fields to collaborate in this much-needed research.

As per the notice, the eight agencies under the NIH will be tasked with different research objectives and will have specific research requests for scientists. Those agencies include the National Cancer Institute (NCI), the National Center for Complementary and Integrative Health (NCCIH), the National Institute on Aging (NIA), the National Eye Institute (NEI), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), the National Institute of Dental and Craniofacial Research (NIDCR) and the National Institute of Neurological Disorders and Stroke (NINDS).

NCCIH is interested in the impact of minor cannabinoids and terpenes on pain, NCI is looking to understand how minor cannabinoids and terpenes can affect cancer treatment, and NIAAA plans on researching how CBD and other cannabinoids can impact alcohol use disorder treatment.

This interest in studying the effects of minor cannabis compounds could signal that federal health agencies are beginning to recognize that marijuana does have therapeutic potential, and the time may not be far off when cannabis policy will be overhauled at the federal level so that legitimate companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) can operate nationally if they so choose.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — House Approves Cannabis Research Measure, Senate Expected to Follow Suit

Earlier last week, the House passed a bipartisan cannabis research measure that would make it easier to conduct necessary medical research on this plant. The Senate is expected to pass the measure soon, which will make this bill the first standalone marijuana reform proposal to be advanced to the president’s desk.

The measure, dubbed the Medical Marijuana and Cannabidiol Research Expansion Act, was considered on the U.S. House of Representatives’ floor under the suspension of rules of parliamentary procedure. This procedure is a motion reserved for noncontroversial initiatives that limits debate in the chamber and allows no amendments. For this procedure to be used, no less than two-third support of the House is needed to approve a measure.

The bill, which was sponsored by Rep. Andy Harris and Rep. Earl Blumenauer, was approved by the House in a 325-to-95 vote. Ahead of the vote, some bipartisan legislators spoke favorably about the bill, with the results showing that all Democrats and the majority of the Republicans were in favor of its passage.

On the floor, Harris stated that this measure would make it easier to carry out more studies on cannabis as the American public deserved to know what medical cannabis was useful for. He noted that it would protect patients as well by modernizing the research techniques used and bringing medical cannabis up to the scientific standards set for every other type of drug sold as medication in America.

In a press release, Blumenauer stated that research was a foundational element of marijuana policy, explaining that it was crucial that scientists were able to fully conduct research on the health benefits of marijuana. He also noted that the federal government had stood in the way of progress and science for a long time, which had imposed barriers for scientists who would like to obtain resources and approval to study marijuana. This bicameral bipartisan measure, he declared, would help to change that.

Frank Pallone, chair of the House Energy and Commerce Committee, also stated on the floor that the bill brought Congress to an overdue historic moment, explaining that studies on cannabis had been regulated in a restrictive way because of the plant’s status as a Schedule I substance. This, he explained, meant that the existing research wasn’t an accurate representation of the products available to most individuals in the country.

Meanwhile, Harris and Blumenauer have also advocated for a separate marijuana research initiative, which cleared the chamber a few months ago.

Once the recently passed cannabis research bill gets the nod from the Senate and is signed by the president, studying marijuana could get a little easier for entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) in their bid to develop products that better serve the diverse needs of the population.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Colorado Firm Set to Conduct Marijuana Research for Alzheimer’s Patients

Over the past decade or so, plenty of studies have found marijuana to be effective at treating the symptoms of a variety of medical conditions. However, most of this research is in its infancy, and experts unanimously agree that we need a lot more clinical trials to definitively prove marijuana’s medical potential.

In Colorado, MedPharma Research, a leading research company in the medical cannabis field, recently announced that it had been granted funding to research the efficacy of marijuana in Alzheimer’s patients. The company submitted a proposal to the Colorado State University Institute of Cannabis Research’s (ICR) FY23 Cannabis Research Opportunity and was ultimately selected for funding.

A panel from the ICR reviewed MedPharma’s proposal and scored it based on approach, significance, environment, broader impact and data analysis. Titled “Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimer’s Disease,” the proposal received praise from the ICR panelists due to its novelty, type of training scientific interns received, and the clarity with which it defined evaluation metrics for every data analysis goal.

Given that Alzheimer’s affects millions of Americans and still has no cure, plenty of people stand to benefit if the research from MedPharma uncovers concrete proof of marijuana’s effectiveness. As it stands, there are a variety of treatments that can be used to alleviate Alzheimer’s symptoms and change the progression of the disease. However, there is no cure for the neurodegenerative disease.

The condition is associated with increased levels of inflammation and oxidative stress in the brain. Cannabidiol (CBD), which has anti-inflammatory and anti-oxidant properties, could be used to treat Alzheimer’s by addressing the inflammatory and oxidative mechanisms behind the disease. Scott Karolchyk, MS, RPh, MedPharma director of formulation and development, notes that CBD also has neuroprotective properties, has proven to be effective in vivo in previous studies, and is nonpsychoactive, making it an even more suitable candidate for research into treatments for Alzheimer’s.

He states that the study will give MedPharma the data it needs to develop innovative, bioavailable and bioequivalent dosage forms. MedPharma President Albert Gutierrez said that undertaking such an unprecedented study is what sets his company apart from other companies in the marijuana research and development game. MedPharma will pursue any means it can to develop therapies to treat Alzheimer’s, he said, and studying how compounds such as CBD function will bring the company one step closer to understanding Alzheimer’s.

MedPharma Director of Pharmacology & Experimental Therapeutics Duncan Mackie, PhD, called the announcement a big win for the cannabinoid research community as a whole, stating that it will offer the first clear cellular and mechanistic evidence on the efficacy of cannabis and cannabinoid products against Alzheimer’s.

This and other ongoing marijuana studies are likely to be followed closely by the cannabis industry and its established actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) since they will add onto the scientific documentation debunking the thinking at the DEA that marijuana has no medical value and should therefore remain a highly controlled substance.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — The Frequency, Implications of Cannabis Use by Millennials

Millions of Americans who grew up during the prohibition era were taught that cannabis is an inherently dangerous drug that encourages drug abuse and criminal activity. To them, cannabis was as dangerous as narcotics such as heroin or cocaine, perhaps even more dangerous because a large focus of the failed war on drugs was on cannabis. The millennial generation, however, generally holds a different view on cannabis compared to older generations.

Nearly 20 states have now passed adult-use cannabis legislation, and in most of these regions, millennials played a significant role in enacting cannabis reform. Sometimes referred to as generation Y, this generation essentially pioneered recreational cannabis reform, at least in the United States, thanks to its ability to be open to new experiences. While older generations can be closed minded, especially regarding controversial issues such as cannabis, millennials are more open minded, putting them at the forefront of social development and change.

A recent survey by market and analytics research firm New Frontier Data sought to understand millennial behaviors and attitudes toward cannabis and their implications. The analytics company found that 39% of the millennials who consume cannabis do so several times a day. Furthermore, the survey revealed that 62% of total cannabis consumption among millennials was recreational, with one of the primary reasons for cannabis use being relaxation.

More than 60% of survey participants said they use both flower and nonflower products while 14% reported using other forms of marijuana exclusively. A majority of the 14% who used other forms of cannabis were women, with 20% of women choosing not to smoke cannabis flower compared to 9% of millennial men.

An estimated 20% of the millennial participants preferred to smoke joints, 14% were more partial to edibles, 9% preferred vapes, and only 6% reported using bongs regularly. Furthermore, 77% of millennials now use cannabis as a substitute for sleep medication, the survey found. The survey also found that 35% of the millennials surveyed used brick-and-mortar stores as their primary source of cannabis, 26% said they get cannabis from friends and family, 20% reported using private dealers and 14% used home-delivery services.

Around 50% said that they usually buy anywhere from $50 to $200 of cannabis with each purchase, and the survey indicated that millennials are more likely to buy more than $200 worth of cannabis per purchase.

Overall, the survey revealed that millennials are more knowledgeable compared to other generations when it comes to cannabis, they are enthusiastic and passionate about cannabis reform, and they are willing to dig deep into their wallets to consume cannabis for both medical and recreational reasons.

Savvy companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) will likely study these survey findings and glean any insights that could help in shaping their future marketing and product development efforts.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.